Record Abstract Submission for BOPA Annual Conference 2026

BOPA is thrilled to announce that we have received an incredible number of 235 abstracts for our annual conference 2026. The record number of abstract is testament to our continued growth and support to practice research in cancer pharmacy. BOPA is committed to support the cancer pharmacy workforce in embedding research and innovation within their practice to develop evidence to guide best practice, in one of our vision pillars.

Abstract marking is now underway and authors of accepted abstract can expect to be informed by Friday 14th August.

Latest News

By BOPA Executive Committee on 1st August 2026

4 Weeks left to Nominate your BOPA Fellowship

4 Weeks left to nominate a BOPA Fellow for 2026. The BOPA Fellowship Scheme Policy has been updated for a clearer nomination and selection process including specific criteria for assessing the nominated individuals.…

Read article
By BOPA Executive Committee on 31st July 2026

Supporting awareness of occupational risks from hazardous medicinal products – BOPA and PASG

Dear BOPA Member, Every day, oncology pharmacy professionals play a vital role in ensuring patients receive safe and effective SACT. Whether preparing, dispensing, transporting or supporting the administration of hazardous…

Read article
By BOPA Executive Committee on 29th July 2026

Publication ALERT – Managing aseptic capacity pressures in systemic anti-cancer therapy services: A national mixed-methods evaluation of UK SACT board guidance implementation

BOPA Publication: Managing aseptic capacity pressures in systemic anti-cancer therapy services: A national mixed-methods evaluation of UK SACT board guidance implementation – Annette (Netty) Cracknell, Dharmisha Chauhan, Lisa Barrott, Emma…

Read article
By BOPA on 24th July 2026

Call for BOPA Award nominations – 1 week left!

It’s awards time – call for nominations! We have had lots of positive feedback from the introduction of the awards dinner at the annual conference, and we are now calling…

Read article